Ticker ALLO – Allogene Therapeutics – sales, description, marketcap – Tickerday.com

ALLO

Allogene Therapeutics

–

Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;

Marketcap: 5.25B; Volume: 386.03K; AvgVol 3m: 593.76K; Beta: –;

Cost estimate:

P/E: –; EPS: -2.11; EPS growth quarter/prev quarter: -27.90%;

EPS growth this year: -4.90%; EPS growth past 5 years: ;

EPS ttm: -2.11;

P/S: ; P/B: 3.89; P/Cashflow: 6.24; P/FCF: ;

Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;

Profitability:

Gross Margin: ; Profit Margin: ; Operating Margin: ;

ROA – return on assets: -27.00%; ROE – return on equity: -30.10%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;

Dividend: –; Dividend Yield (%): –;

Insider Ownership: 3.10%; Insider Transactions:-25.25%;

Institutional Ownership: 64.30%; Institutional Transactions: 19.16%;

Data update: 07.10.2020.